The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
European Commission grants approval of axicabtagene ciloleucel for the treatment of adult patients with R/R DLBCL and HGBL
On October 17, 2022, it was announced that axicabtagene ciloleucel (axi-cel) received marketing authorization by the European Commission for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma who relapse within 12 months of, or are refractory to, first-line chemotherapy.1
This decision is based on data from the landmark ZUMA-7 trial (NCT03391466). Axi-cel demonstrated a 4-fold improvement in event-free survival (8.3 months vs 2 months) at the median 2-year follow-up, a 2.5-fold increase in 2-year event-free survival rates (41% vs 16%) compared with current standard of care (SOC) regimens, and a manageable safety profile.1
In the patient reported outcomes analysis, recently reported on the Lymphoma Hub, axi-cel showed statistically significant and clinically meaningful improvements over SOC by Day 100 for specific quality of life measures. Given the therapeutic benefit of axi-cel over SOC, its approval by the European Commission marks a positive treatment advancement for patients with relapsed/refractory large B-cell lymphoma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
